GlassScriptPhysician profile
David Pineles
NPI 1982081428
$10,667.25
in general payments reported to CMS, 2019-2025
41 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $2,378 · 2023: $2,295 · 2024: $4,035 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,293 · Consulting Fee: $1,500 · Education: $99.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,292.74 |
| Consulting Fee | $1,500.00 |
| Education | $99.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,728.67 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $1,629.33 | 2022-2024 | |
| Abbvie INC. | $1,280.02 | 2021-2025 | |
| Janssen Biotech, INC. | $1,214.06 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $677.15 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $410.37 | 2022-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $362.38 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Evoke Pharma, INC. | $272.88 | 2021-2025 | Gimoti |
| Ardelyx, INC. | $261.70 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $230.52 | 2021-2025 | Suflave, Sutab |
| Redhill Biopharma INC. | $214.54 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Intercept Pharmaceuticals, INC. | $208.11 | 2022-2025 | Ocaliva |
| Pfizer INC. | $194.42 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $186.37 | 2022-2025 | Rebyota |
| Fresenius Kabi USA, LLC | $181.67 | 2023-2024 | Idacio |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $180.09 | 2021-2025 | Acquire, Spyglass, Koala |
| Aimmune Therapeutics, INC. | $162.87 | 2023-2025 | Zenpep |
| Lilly USA, LLC | $153.69 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $124.07 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $119.49 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Gilead Sciences, INC. | $115.02 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $104.68 | 2022-2024 | Dificid |
| Madrigal Pharmaceuticals | $79.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $61.60 | 2023-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $56.35 | 2022-2023 | |
| Novo Nordisk INC | $52.95 | 2025 | Wegovy |
| Vivus LLC | $45.84 | 2021-2022 | |
| Qol Medical, LLC | $42.87 | 2021-2023 | Sucraid |
| Genzyme Corporation | $38.10 | 2022-2025 | |
| Medtronic, INC. | $34.99 | 2021-2024 | Endoflip |
| Olympus America INC. | $34.76 | 2021-2022 | |
| Organon LLC | $32.36 | 2023-2024 | Renflexis |
| Sandoz INC. | $32.04 | 2023 | Hyrimoz |
| Intra-Sana Laboratories | $30.62 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Micro-Tech Endoscopy USA, INC. | $22.36 | 2025 | Edgehog |
| Pentax of America, INC. | $18.31 | 2025 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Blueprint Medicines Corporation | $16.83 | 2023 | Ayvakit |
| Capsovision, INC. | $16.28 | 2024 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $13.70 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2023 | Cyltezo |
| W. L. Gore & Associates, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pineles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.